Monoclonal anti-CD52 antibodies: a potential mode of therapy for parvovirus B(19) hepatitis.
Granot
E
E
Pediatric Gastroenterology-Hepatology Unit, Department of Pediatrics, Hadassah University Hospital, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Miskin
H
H
Aker
M
M
D000410:Alanine Transaminase / Q000097:blood; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm; D001219:Aspartate Aminotransferases / Q000097:blood; D016026:Bone Marrow Transplantation; D000074301:CD52 Antigen; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D010322:Parvoviridae Infections / Q000188:drug therapy*; D016732:Parvovirus B19, Human; D013997:Time Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase